Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked vigilantly but unsuccessfully to create an one-time therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terms of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past several shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set out all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire interview that I came away with a poor opinion of the business.

Irony of irony, the poor opinion of mine of the business has grown steadily, yet the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall relate to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the technology and connected intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 zillion) plus the very first new drug application approval ($five million), and even royalty payments of 5 percent of net sales upon commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and many therapies, it has this single treatments in addition to a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

The opening banner of its on its site (below) shows an active organization with diverse interests albeit focused on leronlimab, multiple illness types, multiple presentations in addition to multiple publications.

Could all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself with the very start of my interest in this particular business. Judging by the multiples of a huge number of several remarks on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this question.

CytoDyn is a classic battleground, or some could say cult stock. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *